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Abstract Zidovudine (ZDV) treat- 
ment during pregnancy, delivery and 
the postnatal period is effective in 
reducing the maternal- infant trans- 
mission of the human immunodefi- 
ciency virus. Reported adverse f- 
fects in the neonate during this long- 
term treatment are bone marrow 
suppression and elevation in aspar- 
tate aminotransferase activity. We 
report a case of severe ZDV-associ- 
ated lactic acidosis in a neonate, 
which resolved rapidly following 
discontinuation of ZDV. The mech- 
anisms leading to this side effect are 
poorly understood. 
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Introduction 
The prophylactic zidovudine (ZDV)  treatment of HIV- 
positive mothers during pregnancy and delivery and of 
her neonate during the first 6 weeks of life has been 
shown to decrease the transmission rate of H IV  from 
26 to 8 % in a recent randomised, double-blind, place- 
bo-controlled trial [1]. The risk-benefit ratio of the re- 
commended regimen clearly favours prophylaxis. There 
are theoretical and rare but severe risks, which, how- 
ever, have to be known when starting prophylactic 
ZDV treatment for a mother and her neonate. 
Case report 
A 16-year-old African primigravida, was diagnosed HIV-positive 
at 24 weeks of gestation (CDC AIDS classification: A2) and re- 
ceived prophylactic ZDV treatment according to Swiss national 
guidelines [2]. Following an uneventful pregnancy, a 2.5-kg girl 
was delivered electively at 35 weeks of gestation by caesarean sec- 
tion under intravenous (i.v.) ZDV administration. Umbilical pH 
was 7.27. Apgar score was 6/5/8. There was progressive onset of se- 
vere respiratory distress due to persistent fetal circulation (PFC) 
diagnosed on the basis of refractory hypoxemia (fractional inspired 
oxygen 1.0, arterial oxygen tension 39 mm Hg, arterial-alveolar 02 
tension ratio 0.06) with normal chest X-ray, absence of congenital 
heart disease and s suprasystemic pulmonary pressure on echo 
Doppler. Treatment included intubation and mechanical ventila- 
tion with morphine sedation, correction of anaemia (haemoglobin 
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Table 1 Clinical and laboratory values before, during and after the 
occurrence of severe lactic acidosis in a zidovudine-treated neo- 
nate (FIO 2 fractional inspired oxygen, PaC02, PaO 2 arterial car- 
bon dioxide and oxygen tensions, BE base excess, ASAT aspartate 
aminotransferase, ALAT alanine aminotransferase, V ventilated, 
N normal, NA not available) 
Age in days 
6 7 8 9 10 11 12 16 
FIO2 (%) 0.30 0.25 
Respiratory rate (min <) V 65 
Heart rate (min -1) 136 140 
Mean arterial pressure (mm Hg) 44 42 
Urine output (ml/kg per h) 5.0 3.2 
Body weight (g) NA 2860 
Enteral formula (ml/24 h) 40 70 
i.v. dextrose-amino acid solution (ml/24 h) 220 210 
Total fluids (ml/kg per 24 h) 104 110 
pH 7.42 7.36 
paco2 (mmHg) 38.6 43.3 
PaO 2 (mmHg) 95.4 109.5 
BE (mmol/1) 0.7 -1.0 
lactic acid (mmol/1) 1.9 NA 
Na (mmol/1) 137 137 
K (mmol/1) 5.6 5.6 
Urea (mmol/1) 3.4 2.9 
Creatinine (mmol/1) 65 69 
ASAT (IU/1) 31 NA 
ALAT (IU/1) 5 NA 
0.29 0.21 0.30 0.28 0.21 0.21 
60 90 V 70 60 50 
152 160 140 158 146 140 
58 68 64 64 60 50 
4.7 3.4 2.6 5.3 2.8 N 
2880 2740 NA 2610 2580 2540 
120 160 0 0 160 420 
190 90 240 300 150 0 
124 100 100 120 124 168 
7.35 7.14 7.36 7.38 7.38 7.36 
47.4 25.3 34.0 42.0 NA NA 
85.2 79.5 91 90 NA NA 
0.9 -18.9 -8.5 -0.1 -1.9 -2.4 
NA 14.0 2.6 2.0 NA NA 
144 142 143 144 141 143 
5.1 5.7 4.0 2.9 6.2 5.9 
NA 7.2 7.2 2.8 NA NA 
NA 64 NA 50 NA NA 
NA 40 96 40 NA NA 
NA 9 13 22 NA NA 
a All day 9 values were collected 2 h prior to reintubation 
103 g/l, mean corpuscular volume 117 fl), inotropic support, alkali- 
nization by hyperventilation a d bicarbonate administration, and 
continuous intravenous magnesium therapy [3]. Ampicillin was 
given from days 1 to 10. Continued ZDV prophylaxis against HIV 
transmission was administered orally at a dose of 2 mg/kg every 
6 h the first day, then with the same dosage i.v. from days 2 to 7 
and orally from days 8to 9. 
PFC resolved over 48 h and the patient was successfully extu- 
bated on day 7 after moderate fluid restriction and three doses of 
frusemide (0.8 mg/kg) on days 5 and 6. Fluids were given according 
to our unit's policy with a dextrose-amino acid solution during the 
first 13 days. The total amount of i.v. amino acids was always less 
than 3.0 g/kg per day. Enteral feeds with formula were started on 
day 2 (i.v. to enteral fluid ratio given in Table 1). 
The patient was doing well, breathing spontaneously in air, par- 
tially enterally fed on day 9, when she developed a sudden onset of 
respiratory distress without haemodynamic instability (Table 1). 
On physical examination, a mild hepatomegaly and five petechial 
lesions on the abdomen were noted. There was no abdominal dis- 
tension or tenderness. Laboratory analysis howed an unexpected 
increase in serum lactate at 14 retool/1 with severe metabolic acido- 
sis partially compensated for by hyperventilation (Table 1) con- 
firmed on repeat analysis. The patient was reintubated due to clin- 
ical worsening of the respiratory distress. Acute management in- 
cluded the administration of 2 mEq/kg of bicarbonate and 10 ml/ 
kg of albumin and discontinuation f both the enteral feeds and 
ZDV treatment. After 18 h the infant was successfully extubated. 
Investigations showed a twofold increase in aspartate amino- 
transferase (ASAT) and a slight increase in urea. Blood glucose, 
blood cell count, coagulation, renal function, serum creatinine ki- 
nase, bilirubin, chest and abdominal X-ray and blood, urine and 
stool cultures were all normal. Lactate and ASAT values returned 
to normal within 6 and 14 h, respectively. The metabolic acidosis 
disappeared over 24 h without repeated bicarbonate administra- 
tion. More common causes for lactic acidosis uch as hypoxia, shock 
or hypotension were excluded on a clinical basis (cf. also Table 1). 
The patient was discharged on day 28. ZDV treatment has not 
been reinstated and no alternative antiviral prophylactic treatment 
introduced. At 11-month follow-up, the patient showed no clinical 
or serological signs of HIV infection, no metabolic acidosis and 
normal growth and development. 
Discussion 
Zidovudine ,  a nucleos ide ana logue phosphory la ted  by 
thymid ine k inase in heal thy and H IV - in fec ted  cells, is a 
potent  inhib i tor  of H IV  reverse t ranscr iptase and has 
also a weak aff inity for the mammal  DNA po lymerase-  
Y. Usual  adverse effects in the neonate  are a mi ld mac- 
rocytic anaemia  and a sl ight increase in ASAT [4]. 
Anaemia  is cons idered to be due to the sensit ivity of er- 
ythrocyte precursor  cells to ZDV. The increase in ASAT 
may be of hepat ic  or muscular  origin and usual ly has a 
benign course. Both  side effects were observed in this 
pat ient  with no major  consequences.  
Severe lactic acidosis in ZDV- t reated  adults was re- 
cently descr ibed.  Chat tha  et al. [5] repor ted  seven 
A IDS pat ients (aged 43 + 8 years)  with card iovascular  
col lapse and severe lactic acidosis (14.3 + 2.6 mmol/1), 
despite having normal  cardiac funct ion and oxygen de- 
livery. Four  of these pat ients  were receiv ing long-term 
ZDV therapy. It was conc luded that ZDV-assoc ia ted  
lactic acidosis was a major  comorb id  event  leading to 
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death. Since then, other similar adult cases have been 
reported [6]. 
In this patient, the development of lactic acidosis on 
day 9 resolved rapidly following discontinuation of 
ZDV. This suggests that ZDV therapy alone or in con- 
junction with other factors may be responsible for this 
side effect. There was no clear evidence implicating a
more common cause for lactic acidosis, like circulatory 
insufficiency, infection or metabolic imbalance. The pa- 
tient was in good clinical condition when the acidosis 
suddenly developed over a few hours. Although mild hy- 
povolaemia may have contributed, it is unlikely to be a 
major causative factor underlying the severe acidotic 
episode. The only clinical signs (mild liver enlargement 
and a few petechiae) were not consistent with any par- 
ticular aetiology. In the absence of a more likely cause a 
pharmacological explanation has to be considered. 
Plasma levels of ZDV were not determined in this 
case, therefore a pharmacokinetic explanation for the 
observed toxic event can be hypothesised but not 
proved. The dose of ZDV given to this 35-week-old in- 
fant was that recommended forneonates [2]. One could 
argue that administering the same dose i.v. as the orally 
recommended one may have played a role. However, 
since a decreased first-pass metabolism and a greater 
bioavailability of ZDV (89 vs 60-70%) have been 
shown in neonates after oral administration compared 
to infants [7], the increase in the drug exposure follow- 
ing i.v. administration is minimal and unlikely to play a 
crucial role in the adverse vent. 
Total body clearance of ZDV is influenced by gesta- 
tional age and liver metabolic maturity because ZDV is 
mainly eliminated by hepatic metabolism to a glucuro- 
nide compound. The rest undergoes tubular enal excre- 
tion. The serum half-life is 3 h in neonates compared to 
nearly 2 h in older infants [7]. Competition for ZDV 
glucuronidation with endogenous substrates (bilirubin) 
or durgs (morphine) is a possible interaction leading to 
increased plasma levels. Furthermore, it has been shown 
that renal ZDV excretion can be inhibited by drugs 
transported by either the tubular organic anion or ca- 
tion transport system [8]. Drug interaction at this level 
(with morphine and frusemide in this case), in addition 
to immature renal function, is therefore a possibility. 
This patient did receive these drugs, but only during 
the first 6 days and at minimal dosage, which makes 
their potential interaction negligible. 
The adult cases usually show a latency of several 
months between the initiation of ZDV treatment and 
the occurrence of lactic acidosis. This patient was ex- 
posed to ZDV during nearly 3 months, as this drug easi- 
ly crosses the placenta. To our knowledge, there is no ex- 
planation why there is such a long delay between the 
start of ZDV treatment and the development of lactic 
acidosis. A subclinical direct cytotoxic effect may be hy- 
pothesised: the affinity of ZDV for mitochondrial DNA 
polymerase-7 reduces mitochondrial DNA synthesis, 
which may contribute to a delayed cytotoxicity as shown 
in vitro [9]. This may lead to increased lactate produc- 
tion by reducing the oxidation of the reduced form of ni- 
cotinamide-adenine dinucleotide (NAD) to NAD+ [10]. 
It is questionable whether the initial persistent fetal 
circulation or another unrecognised condition may 
have played a role in the pathogenesis of the lactic 
acidosis in this patient, possibly by unmasking a sub- 
clinical biological toxicity. The occurrence several days 
after the recovery of the circulatory problems, the fact 
that lactate values were normal before the collapse, 
and the good clinical condition of the patient when the 
lactate increased to not support his hypothesis. 
The recommended length of neonatal prophylactic 
ZDV therapy is 6 weeks, a decision based on the risk of 
finding maternal infected cells in the neonate's circula- 
tion during the first few weeks of life. This case could 
contribute in the decision making concerning the opti- 
mal length of neonatal ZDV therapy when considering 
the risk-benefit ratio. 
In conclusion, severe lactic acidosis is a life-threaten- 
ing, though rare, side effect of neonatal ZDV therapy of 
which the paediatric and neonatal intensivist must be 
aware. The optimal ength of postnatal therapy has still 
to be established and should consider this possible com- 
plication. We cannot conclude whether the severe lactic 
acidosis een in this patient was dose-dependent. 
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